Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kyowa Kirin Head Sees Major Global Status For Newly Formed Biotech

This article was originally published in PharmAsia News

Executive Summary

Kyowa Kirin intends to go head to head in 2012 with the world's largest biotechnology companies, the president of the recently formed Japanese company says. Created through a merger of Kyowa Hakko Kogyo and Kirin Pharma last October, the company is banking on its advanced antibody technologies to help it catch up with big biotechs such as Amgen and Genentech of the United States. The key technologies in that effort are Potelligent and Complegent, already licensed to 10 drug makers, including major multinationals. Kyowa Kirin President Yuzuru Matsuda anticipates blockbuster status for drugs derived from the technologies, which would lead to a "rain fall" of royalties for the company. (Click here for more - a subscription may be required
Advertisement

Related Content

Kyowa Hakko Kirin Licenses Anti-LIGHT MAB To Sanofi-Aventis
Advertisement
UsernamePublicRestriction

Register

SC069886

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel